Similar articles

• Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.

  Weishaar RE, Quade MM, Schenden JA, Evans DB. Weishaar RE, et al. J Cyclic Nucleotide Protein Phosphor Res. 1985;10(6):551-64. J Cyclic Nucleotide Protein Phosphor Res. 1985. PMID: 3003170
• Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.

  Brunkhorst D, von der Leyen H, Meyer W, Schmidt-Schumacher C, Scholz H. Brunkhorst D, et al. Arzneimittelforschung. 1988 Sep;38(9):1293-8. Arzneimittelforschung. 1988. PMID: 2852013
• Tissue and species specificity of cardiac cAMP-phosphodiesterase inhibitors.

  Pang DC. Pang DC. Adv Second Messenger Phosphoprotein Res. 1992;25:307-20. Adv Second Messenger Phosphoprotein Res. 1992. PMID: 1313264 Review. No abstract available.
• Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.

  Ukita T, Sugahara M, Terakawa Y, Kuroda T, Wada K, Nakata A, Ohmachi Y, Kikkawa H, Ikezawa K, Naito K. Ukita T, et al. J Med Chem. 1999 Mar 25;42(6):1088-99. doi: 10.1021/jm980314l. J Med Chem. 1999. PMID: 10090791
• Cyclic AMP phosphodiesterase from human heart and drug action.

  Tanaka T, Masuoka H, Ito M, Nakano T, Naka M, Hidaka H. Tanaka T, et al. Adv Second Messenger Phosphoprotein Res. 1992;25:373-81. Adv Second Messenger Phosphoprotein Res. 1992. PMID: 1313268 Review. No abstract available.